Starting July 1, 2026, Medicare opens the door to GLP-1 weight-loss meds for seniors. Who qualifies? Well, if you’re over 65, have a BMI of 35 or higher, and thankfully don’t have type 2 diabetes, you might be in luck. There’s a $50 monthly copay, but don’t think that counts toward your deductible. This is a temporary gig until the fancy BALANCE Model rolls out in 2027. Curious about all the details? More info is just ahead.
Design Highlights
- Medicare will cover specific GLP-1 medications, including Wegovy and Zepbound, starting July 1, 2026.
- Eligible beneficiaries must have a BMI of 35 or higher, with some exceptions for health issues.
- A flat monthly copay of $50 is required, not counting toward deductibles or out-of-pocket limits.
- Prior authorization is necessary, documenting BMI and qualifying conditions at the start of therapy.
- This program serves as a temporary bridge until the BALANCE Model launches in 2027.
Key Dates and Coverage for Medicare’s GLP-1 Bridge
Starting July 1, 2026, Medicare will roll out its GLP-1 Bridge demonstration, which is really just a fancy way of saying they’re trying to bridge the gap until the BALANCE Model launches in 2027. This demo runs until December 31, 2027—because apparently, they can’t make things permanent right away. Covered drugs? Think Wegovy and Zepbound. Yes, it’s all about weight loss—because why not? Forget your usual Part D coverage; this is temporary and designed just for this moment. Beneficiaries will pay a cool $50 a month for their GLP-1 fix, but don’t get too excited; it doesn’t count toward your out-of-pocket limit. Moreover, a single central processor will handle prior authorization and claims adjudication to streamline the process. The Bridge is available to eligible Medicare beneficiaries enrolled in standalone PDPs or Medicare Advantage plans, so jump through those hoops! This shift marks a significant departure from the 2003 Medicare Modernization Act, which previously barred Medicare from covering weight loss medications altogether.
Eligibility Criteria: Who Can Benefit From the GLP-1 Bridge?
Guiding the eligibility maze for Medicare’s GLP-1 Bridge can feel like deciphering a secret code. Who’s in? Here’s the scoop:
- Age 18 or older? Check.
- You need Part D prescription drug coverage. No exceptions.
- A BMI of 35 or higher? You’re golden.
- Struggling with certain health issues? You might still qualify with a lower BMI.
But hold on! If you have type 2 diabetes or moderate-to-severe sleep apnea, you’re out. And let’s not forget—this bridge is temporary, running from July 2026 to December 2027. Additionally, coverage for specified GLP-1s will officially begin on July 1, 2026. This program aims to enhance access to innovative treatments for eligible seniors.
Importantly, your BMI and any qualifying conditions must be documented at therapy initiation, meaning you cannot rely on measurements taken after you have already begun losing weight on a GLP-1 medication.
How Much Will You Pay? Understanding Your Copay and Coverage?
When it comes to the Medicare GLP-1 Bridge, the price tag is straightforward—$50 a month, no surprises. Seriously, just $50. That’s your flat copay, whether you’re rolling in cash or counting pennies. This sweet deal starts on July 1, 2026, and lasts until December 31, 2027. You’ll pay this at the pharmacy when you pick up your one-month supply of approved drugs—think Wegovy or Foundayo. But hold your horses: it doesn’t count toward your deductible or the out-of-pocket limit. The remaining cost is covered by a government subsidy of approximately $350 per month per participant, significantly closing the gap between what beneficiaries pay and the drug’s actual price. Additionally, the program is part of a broader initiative to expand Medicare coverage of GLP-1 medications for weight loss. This pilot program is intended to serve as a short-term initiative leading up to a potential longer-term solution in 2028.
